A detailed history of Nisa Investment Advisors, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 372 shares of CGEM stock, worth $2,812. This represents 0.0% of its overall portfolio holdings.

Number of Shares
372
Previous 280 32.86%
Holding current value
$2,812
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 23, 2025

BUY
$5.93 - $8.34 $545 - $767
92 Added 32.86%
372 $2,000
Q2 2025

Jul 31, 2025

BUY
$7.13 - $9.08 $1,283 - $1,634
180 Added 180.0%
280 $2,000
Q1 2025

Apr 30, 2025

SELL
$7.57 - $12.68 $340 - $570
-45 Reduced 31.03%
100 $0
Q4 2024

Jan 17, 2025

SELL
$10.77 - $17.6 $904 - $1,478
-84 Reduced 36.68%
145 $1,000
Q3 2024

Oct 24, 2024

BUY
$16.03 - $20.86 $1,025 - $1,335
64 Added 38.79%
229 $3,000
Q2 2024

Jul 19, 2024

BUY
$15.63 - $29.35 $422 - $792
27 Added 19.57%
165 $2,000
Q1 2024

May 01, 2024

BUY
$10.17 - $19.02 $213 - $399
21 Added 17.95%
138 $2,000
Q4 2023

Jan 25, 2024

SELL
$7.89 - $10.23 $189 - $245
-24 Reduced 17.02%
117 $1,000
Q3 2023

Nov 02, 2023

BUY
$9.05 - $11.72 $226 - $293
25 Added 21.55%
141 $1,000
Q2 2023

Aug 11, 2023

BUY
$8.8 - $13.4 $941 - $1,433
107 Added 1188.89%
116 $1,000
Q1 2023

May 02, 2023

SELL
$10.2 - $11.91 $141,688 - $165,441
-13,891 Reduced 99.94%
9 $0
Q4 2022

Feb 02, 2023

SELL
$9.72 - $13.62 $32,474 - $45,504
-3,341 Reduced 19.38%
13,900 $147,000
Q3 2022

Nov 07, 2022

BUY
$11.82 - $15.42 $39,490 - $51,518
3,341 Added 24.04%
17,241 $222,000
Q2 2022

Aug 03, 2022

BUY
$7.31 - $13.55 $101,609 - $188,345
13,900 New
13,900 $178,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $345M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.